Blueprint
 
FORM 6-K / A
 
 
 
 
SECURITIES AND EXCHANGE COMMISSION

 
Washington D.C. 20549
 
 
 
 
Report of Foreign Issuer
 
 
 
 
Pursuant to Rule 13a-16 or 15d-16 of

 
the Securities Exchange Act of 1934
 
 
 
 
 
For period ending 26 July 2017
 
 
 
GlaxoSmithKline plc
 
(Name of registrant)

 
 
 
 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
 
(Address of principal executive offices)

 
 
 
 
 
Indicate by check mark whether the registrant files or
 
will file annual reports under cover Form 20-F or Form 40-F

 
 
 
 
 
Form 20-F x     Form 40-F

 
 
 
--

 
 
 
Indicate by check mark whether the registrant by furnishing the
 
information contained in this Form is also thereby furnishing the
 
information to the Commission pursuant to Rule 12g3-2(b) under the
 
Securities Exchange Act of 1934.

 
 
 
 
 
Yes      No x
 
 
 
The following amendment has been made to the Director/PDMR Shareholding announcement released on 27 April 2017 in respect of the volume of notional Ordinary Shares acquired by Mr Urs Rohner (Independent Non-Executive Director) under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2017 to 31 March 2017.
 
Price(s) and volume(s)
Price(s)
Volume(s)
£15.83
454.043
 
 
 
All other details remain unchanged.
 
The full amended text is shown below.
 
 
 
 GlaxoSmithKline plc (the 'Company')
 
Transaction notification
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Philip Hampton
b)
Position/status
Non-Executive Chairman
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
  
 
b)
Nature of the transaction
Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2017 to 31 March 2017.
 
c)
Price(s) and
volume(s)
Price(s)
Volume(s)
£15.83
2,763.740
d)
Aggregated information
 
Aggregated volume Price
n/a (single transaction)
 
 
 
 
 
e)
Date of the transaction
2017-04-26
f)
Place of the transaction
 
n/a
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Professor Sir Roy Anderson
b)
Position/status
Independent Non-Executive Director
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
 
 
b)
Nature of the transaction
Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2017 to 31 March 2017.
c)
Price(s) and
volume(s)
Price(s)
Volume(s)
£15.83
454.043
d)
Aggregated information
 
Aggregated volume Price
n/a (single transaction)
 
 
 
 
 
 
e)
Date of the transaction
2017-04-26
f)
Place of the transaction
 
n/a
 

 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr Vindi Banga
b)
Position/status
Senior Independent Non-Executive Director
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
   
 
 
b)
Nature of the transaction
Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2017 to 31 March 2017.
c)
Price(s) and
volume(s)
Price(s)
Volume(s)
£15.83
1,816.172
d)
Aggregated information
 
Aggregated volume Price
n/a (single transaction)
 
 
 
 
 
 
e)
Date of the transaction
2017-04-26
f)
Place of the transaction
 
n/a
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Dr Vivienne Cox
b)
Position/status
Independent Non-Executive Director
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
  
 
 
b)
Nature of the transaction
Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2017 to 31 March 2017.
c)
Price(s) and
volume(s)
Price(s)
Volume(s)
£15.83
335.597
d)
Aggregated information
 
Aggregated volume Price
n/a (single transaction)
 
 
 
 
 
 
e)
Date of the transaction
2017-04-26
f)
Place of the transaction
 
n/a
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms Lynn Elsenhans
b)
Position/status
Independent Non-Executive Director
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
American Depositary Shares ('ADSs')
ISIN: US37733W1053
 
  
 
b)
Nature of the transaction
Acquisition of notional ADSs under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2017 to 31 March 2017.
c)
Price(s) and
volume(s)
Price(s)
Volume(s)
$41.13
1,202.913
d)
Aggregated information
 
Aggregated volume Price
n/a (single transaction)
 
 
 
 
 
 
e)
Date of the transaction
2017-04-26
f)
Place of the transaction
 
n/a
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Dr Jesse Goodman
b)
Position/status
Independent Non-Executive Director
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
American Depositary Shares ('ADSs')
ISIN: US37733W1053
 
  
 
b)
Nature of the transaction
Dr Jesse Goodman was appointed to the Board with effect from 1 January 2016, as previously announced, and in accordance with the share allocation arrangements for Independent Non-Executive Directors, 25% of his fees were retained to be reinvested in notional ADSs at a date to be mutually agreed.
The accumulated balance of the retained fees has now been reinvested as disclosed below.
Going forward, notional ADSs of the Company will be allocated on a quarterly basis.
Acquisition of notional ADSs under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2016 to 31 March 2017.
c)
Price(s) and
volume(s)
Price(s)
Volume(s)
$41.13
1,739.846
d)
Aggregated information
 
Aggregated volume Price
n/a (single transaction)
 
e)
Date of the transaction
2017-04-26
f)
Place of the transaction
 
n/a
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms Judy Lewent
b)
Position/status
Independent Non-Executive Director
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
American Depositary Shares ('ADSs')
ISIN: US37733W1053
 
 
 
b)
Nature of the transaction
Acquisition of notional ADSs under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2017 to 31 March 2017.
c)
Price(s) and
volume(s)
Price(s)
Volume(s)
$41.13
449.364
d)
Aggregated information
 
Aggregated volume Price
n/a (single transaction)
 
 
 
 
 
 
e)
Date of the transaction
2017-04-26
f)
Place of the transaction
 
n/a
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr Urs Rohner
b)
Position/status
Independent Non-Executive Director
c)
Initial notification/
amendment
Amendment
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
 
b)
Nature of the transaction
Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2017 to 31 March 2017.
c)
Price(s) and
volume(s)
Price(s)
Volume(s)
£15.83
454.043
d)
Aggregated information
 
Aggregated volume Price
n/a (single transaction)
 
 
 
 
 
 
e)
Date of the transaction
2017-04-26
f)
Place of the transaction
 
n/a
 
 
 
 
 
SIGNATURES
 
 
 
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

 
 
GlaxoSmithKline plc
 
(Registrant)
 
 
Date: July 26, 2017 
 
 
 
 
By: VICTORIA WHYTE
--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GlaxoSmithKline plc